RecruitingNCT04645199

National Longitudinal Cohort of Hematological Diseases

National Longitudinal Cohort of Hematological Diseases (NICHE)


Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

2,300 participants

Start Date

Dec 1, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood diseases, the treatment methods, prognosis and medical expenses of these patients in China. Method The study will include patients diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, large granular lymphocyte leukemia, essential thrombocythemia, blood infection or received bone marrow transplantation in the investigating hospitals from January 1, 2020, and collect basic information, diagnostic and treatment information, prognosis information, as well as medical expense information from medical records. In its current form, the NICHE registry incorporates historical data (collected from 2000) and is systematically collecting prospective data in two phases with broadening reach, and prospectively follow-up to collect the prognosis information.


Eligibility

Plain Language Summary

Simplified for easier understanding

This is an observational study — it collects data over time from patients with blood diseases to better understand how these conditions progress and respond to treatment. No experimental drug is involved. **You may be eligible if...** - You were diagnosed at one of the participating hospitals on or after January 1, 2020 - You have one of the following: acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, a bleeding disorder, or have received a bone marrow transplant **You may NOT be eligible if...** - Long-term follow-up is not possible (for example, due to moving away or having a severe illness) - You have alcohol or drug dependency that would affect your ability to participate - Your doctor believes participating would put your safety at risk Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04645199


Related Trials